Agios Pharmaceuticals to Highlight Progress at Major Healthcare Event
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative approach to cellular metabolism and pioneering therapies for rare diseases, is gearing up to present at a significant healthcare event. Scheduled for mid-May, the 2025 RBC Capital Markets Global Healthcare Conference will serve as a platform for Agios to share its advancements in the field.
Conference Details and Access
This key event will take place on May 21, at 8:00 am ET, where Agios’s management team is set to take the stage. Interested participants can access a live webcast through the Investors section of the company’s website under the "Events & Presentations" tab. Following the live event, a replay will be available on their website for at least two weeks, ensuring that those unable to attend live can stay informed.
About Agios Pharmaceuticals and Its Commitment to Rare Diseases
Agios Pharmaceuticals is distinguished as a leader in pyruvate kinase (PK) activation, focusing on the development of transformative therapies for patients affected by rare diseases. In the U.S., the company markets a first-in-class PK activator specifically designed for adults living with PK deficiency—the first therapy to effectively modify the disease course of this debilitating condition. This dedication showcases Agios's commitment not just to innovation, but to changing the lives of those with rare diseases.
Expanding Clinical Programs
Building on their expertise in hematology and cellular metabolism, Agios is advancing a robust clinical pipeline. Currently, their investigational medicines work towards addressing conditions such as alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, and myelodysplastic syndromes (MDS)-associated anemia, as well as phenylketonuria (PKU). This strategic focus on clinical trials underscores their drive to improve patient outcomes through scientific advancements.
Innovative Research and Development
Beyond ongoing clinical trials, Agios is making strides in preclinical research, notably with a TMPRSS6 siRNA project aimed at treating polycythemia vera. This research aligns with their vision of not only introducing effective therapies but establishing a comprehensive approach to managing rare hematologic maladies.
Contact Information for Investors and Media
To facilitate communication, Agios has made available direct contact details for their investor relations and corporate communications teams. Chris Taylor, Vice President of Investor Relations and Corporate Communications, is the point of contact for investor inquiries. Additionally, Eamonn Nolan, Senior Director of Corporate Communications, is available for media-related questions. Both can be reached via email, with the company fostering an open channel for dialogue with stakeholders.
Frequently Asked Questions
What is the focus of Agios Pharmaceuticals?
Agios focuses on developing therapies for rare diseases, particularly through their expertise in cellular metabolism and PK activation.
When will Agios present at the RBC Capital Markets Global Healthcare Conference?
The presentation is scheduled for May 21, at 8:00 am ET, with a live webcast available on their website.
What notable products does Agios market?
Agios markets a first-in-class PK activator for adults with PK deficiency, addressing an unmet need for patients suffering from this rare condition.
What is Agios's approach to research and development?
Agios is dedicated to both clinical and preclinical research, advancing a diverse pipeline aimed at improving outcomes for various rare hematological diseases.
How can interested parties contact Agios for more information?
Investors and media can reach Agios through designated contacts, Chris Taylor for investor relations and Eamonn Nolan for media inquiries.
